Atherogenic dyslipidemia and the metabolic syndrome: Pathophysiological mechanisms;Aterogenní dyslipidémie a metabolický syndrom: Patofyziologické mechanismy

Casopis Lekaru Ceskych

Volumn 147, Issue 9, 2008, Pages 459-470

  Žák, Aleš ^a   Slaby A ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Atherogenic dyslipidemia; Hypertriglyceridemia; Insulin resistance; Low density lipoprotein size; Reverse cholesterol transport

Indexed keywords

CHOLESTEROL; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; DYSLIPIDEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; METABOLISM; REVIEW;

ATHEROSCLEROSIS; CHOLESTEROL; CHOLESTEROL, HDL; DYSLIPIDEMIAS; FATTY ACIDS; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X;

EID: 54449100811     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Superko, H. R.: Beyond LDL cholesterol reduction. Circulation. 1996, 94, s. 2351-2354.
2. Petersen, K. F., Shulman, G. I.: Etiology of insulin resistance. Am. J. Med, 2006, 119 (Suppl. 5A). s. 10S-16S.
3. Laakso, M.: Gene variants, insulin resistance, and dyslipidaemia. Curr. Opin. Lipidol., 2004, 15, s. 115-120.
4. Miranda, P. J., DeFronzo, R. A., Califf, R. M. et al.: Metabolic syndrome: Definition, pathophysiology, and mechanisms. Am. Heart J., 2005, 149, s. 33-45.
5. Le Roith, D., Zick, Y.: Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care, 2001, 24, s. 588-597.
6. Cusi, K., Maezono, K., Osman, A. et al.: Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J. Clin. Invest., 2000. 105, s. 311-320.
7. Avramoglu, R. K., Basciano, H., Adeli, K.: Lipid and lipoprotein dysregulation in insulin resistant states. Clin. Chim. Acta. 2006, 368, s. 1-19.
8. Lewis, G. F., Carpentier, A., Adeli, K. et al.: Disordered tat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr. Rev, 2002, 23, s. 201-229.
9. Gregor, M. F., Hotamisligil, G. S.: Thematic review series: Adipocyte biology: The endoplasmic reticulum and metabolic disease. J. Lipid Res., 2007, 48, s. 1905-1914.
10. Sharma, A. M.: The obese patient with diabetes mellitus: From research targets to treatment options. Am. J. Med., 2006, 119 (Suppl. 5A), s. 17S-23S.
11. Fisler, J. S., Warden, C. H.: Uncoupling proteins, dietary fat and the metabolic syndrome. Nutr. Metab., 2006, 3, 38. doi: 10.1186/1743-7075-3-38.
12. Lara-Castro, C., Luo, N., Wallace, P. et al.: Adiponectin multinieric complexes and the metabolic syndrome trait cluster. Diabetes. 2006, 55, s. 249-259.
13. Bouloumié, Á., Curat, C. A., Sengenés, C. et al.: Role of macrophage tissue infiltration in metabolic diseases. Curr. Opin. Clin. Nutr. Metab. Care, 2005, 8, s. 347-354.
14. Sonnenberg, G. E., Krakower, G. R., Kissebah, A. H.: A novel pathway to the manifestations of metabolic syndome. Obes. Res., 2004, 12, s. 180-186.
15. Hokanson, J. E., Austin, M. A.: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J. Cardiovasc. Risk, 1996, 3, s. 213-219.
16. Adeli, K., Taghibiglou, C., Van Iderstine, S. C. et al.: Mechanisms of hepatic very low-density lipoprotein overproduction. Trends Cardiovasc. Med., 2001, 11, s. 170-176.
17. Chan, D. C., Barrett, P. H., Watts, G. F.: Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. Curr. Opin. Lipidol., 2006, 17, s. 28-36.
18. Krauss, R. M., Siri, P. W.: Metabolic abnormalities: Triglyceride and low-density lipoprotein. Endocrinol. Metab. Clin. North Am., 2004, 33, s. 405-415.
19. Ginsberg, H. N., Zhang, Y.-L., Hernandez-Ono, A.: Metabolic syndrome: Focus on dyslipidemia. Obesity, 2006, 14 (Suppl.), s. 41S-49S.
20. Rangan, V. S., Smith, S.: Fatty acid synthesis in eukaryotes. In: Biochemistry of lipids, lipoproteins and membrane. Vance, D. E. Vance, J. E. (eds.), 4th ed. Amsterdam, Elsevier Science B.V., 2002, s. 151-179.
21. Olivecrona, T., Bergo, M., Hultin, M. et al.: Nutritional regulation of lipoprotein lipase. Can. J. Cardiol., 1995, 11 (Suppl.), s. 73G-78G.
22. Chan, D. C., Barrett, P. H., Watts, G. F.: Lipoprotein transport in the metabolic syndrome: Pathophysiological and interventional studies employing stable isotopy and modelling metods. Clin. Sci., 2004, 107, s. 233-249.
23. Deeb, S. S., Zambon, A., Carr, M. C. et al.: Hepatic lipase and dyslipidemia: Interactions among genetic variants, obesity, gender, and diet. J. Lipid Res., 2003, 44, s. 1279-1286.
24. Lewis, G. F., Rader, D. J.: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res., 2005, 96, s. 1221-1232.
25. Després, J. P., Lemieux, I., Dagenais, G. R. et al.: HDL-cholesterol as a marker of coronary heart disease risk: The Quebec Cardiovascular Study. Atherosclerosis, 2000, 153, s. 263-272.
26. rd ed. Philadelphia, Lippincott, Williams & Wilkins, 2003.
27. Malik, S.: Transcriptional regulation of the apolipoprotein AI gene. Front. Biosci., 2003, 8, s. d360-d368.
28. Horowitz, B. S., Goldberg, I. J., Merab, J. et al.: Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J. Clin. Invest., 1993, 91, s. 1743-1752.
29. Rye, K. A., Bright, R., Psaltis, M. et al.: Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E. J. Lipid Res., 2006, 47, s. 1025-1036.
30. Jahangiri, A., Rader, D. J., Marchadier, D. et al.: Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I. J. Lipid Res., 2005, 46, s. 896-903.
31. . Murakami, M., Kudo, I.: New phospholipase A(2) isozymes with a potential role in atherosclerosis. Curr. Opin. Lipidol., 2003, 14, s. 431-436.
32. Hammad, S.M., Barth, J. L., Knaak, C. et al.: Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins. J. Biol. Chem., 2000, 275, s. 12003-12008.
33. Rothblat, G. H., Llera-Moya, M., Atger, V. et al.: Cell cholesterol efflux: Integration of old and new observations provides new insights. J. Lipid. Res., 1999, 40, s. 781-796.
34. Schwartz, C. C., VandenBroek, J. M., Cooper, P. S.: Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J. Lipid. Res., 2004, 45, s. 1594-1607.
35. Wadham, C., Albanese, N., Roberts, J. et al.: High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation, 2004, 109, s. 2116-2122.
36. Barter, P. J., Puranik, R., Rye, K. A.: New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease. Curr. Cardiol. Rep., 2007, 9, s. 493-498.
37. Lamarche, B. A., St-Pierre, A. C., Ruel, I. L. et al.: A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can. J. Cardiol., 2001, 17, s. 859-865.
38. Sevanian, A., Hwang, J., Hodis, H. et al.: Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arteioscler. Thromb. Vase. Biol., 1996, 16, s. 784-793.
39. Davidsson, P., Hulthe, J., Fagerberg, B. et al.: A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J. Lipid Res., 2005, 46, s. 1999-2006.
40. Berneis, K. K., Krauss, R. M.: Metabolic origins and clinical significance of LDL heterogeneity. J. Lipid Res., 2002, 43, s. 1363-1379.
41. Vessby, B.: Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr. Opin. Lipidol., 2003, 14, s. 15-19.
42. Warensjö, E., Sundström, J., Lind, L. et al.: Factor analysis of fatty acids in serum lipids as a measure of dietary fat quality in relation to the metabolic syndrome in men. Am. J. Clin. Nutr., 2006, 84, s. 442-448.
43. Žák, A., Vecka, M., Tvrzická, E. et al.: Složení esterifikovaných mastných kyselin a lipoperoxidace u metabolického syndromu. Čas. Lék. čes., 2007, 146, s. 484-491.
44. Evans, J. L., Goldfine, I. D., Maddux, B. A. et al.: Oxidative stress and stress-activated signaling pathways: A unifying hypothesis of type 2 diabetes. Endocrine Rev., 2002, 23, s. 599-622.
45. Laaksonen, D. E., Lakka, T. A., Lakka, H.-M. et al.: Serum fatty acid composition predicts development of impaired fasting glycaemia and diabetes in middle-aged men. Diabet. Med., 2002, 19, s. 456-464.
46. Leskinen, M. H., Solakivi, T., Kunnas, T. et al.: Serum fatty acids in postinfarction middle-aged men. Scand. J. Clin. Lab. Med., 2005, 65, s. 485-490.
47. Decsi, T., Csábi, G., Török, K. et al.: Polyunsaturated fatty acids in plasma lipids of obese children with and without metabolic cardiovascular syndrome. Lipids, 2000, 35, s. 1179-1184.
48. Klein-Platat, C., Drai, J., Oujaa, M. et al.: Plasma fatty acid composition is associated with the metabolic syndrome and low grade inflammation in overweight adolescents. Am. J. Clin. Nutr., 2005, 82, s. 1178-1184.
49. Simonen, P. P., Gylling, H., Miettinen, T. A.: Introducing a new component of the metabolic syndrome: low cholesterol absorption. Am. J. Clin. Nutr., 2000, 72, s. 82-88.
50. Simonen, P. P., Gylling, H., Miettinen, T. A.: Body weight modulates cholesterol metabolism in non-insulin dependent type 2 diabetics. Obesity Res., 2002, 5, s. 328-335.
51. Gylling, H., Tuominen, J. A., Koivisto, V. A. et al.: Cholesterol metabolism in type 1 diabetes. Diabetes, 2004, 53, s. 2217-2222.
52. Haffner, S. M.: Risk constellations in patients with the metabolic syndrome: Epidemiology, diagnosis, and treatment patterns. Am. J. Med., 2006, 119 (Suppl. 5A), s. 3S-9S.
53. Richardi, G., Giacco, R., Rivellese, A. A.: Dietary fat, insulin sensitivity and the metabolic syndrome. Clin. Nutr., 2004, 23, s. 447-456.
54. Chong, M. F., Fielding, B. A., Frayn, K. N.: Mechanisms for the acute effect of fructose on postprandial lipemia. Am. J. Clin. Nutr., 2007, 85, s. 1511-1520.
55. Berglund, L., Lefevre, M., Ginsberg, H. N. et al.: Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states. Am. J. Clin. Nutr., 2007, 86, s. 1611-1620.
56. Lombardo, Y. B., Chicco, A. G.: Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. J. Nutr. Biochem., 2006, 17, s. 1-13.
57. Žák, A., Tvrzická, E., Zeman, M. et al.: Patofyziologie a klinický význam vícenenasycených mastných kyselin řady n-3. Čas. Lék. čes., 2005, 144 (Suppl. 1), s. 6-18.
58. Watts, G. F., Barrett, P. H., Ji, J. et al.: Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes, 2003, 52, s. 803-811.
59. Shepherd, J., Betteridge, J., Van Gaal, L. et al.: Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: A position paper developed by a European Consensus Panel. Curr. Med. Res. Opin., 2005, 21, s. 665-682.
60. Nagashima, K., Lopez, C., Donovan, D. et al.: Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J. Clin. Invest., 2005, 115, s. 1323-1332.
61. . Lefebvre, F., Chinetti, C., Fruchart, J.-C. et al.: Sorting out the role of PPARalpha in energy metabolism and vascular homeostasis. J. Clin. Incest., 2006, 116, s. 571-580.
62. Štulc, T., Češka, R.: Duální blokáda receptorů PPAR. Farmakoterapie, 2006, 2, s. 13-16.
63. Nissen, S. E., Wolski, K., Topol, E. J.: Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005, 294, s. 2581-2586.
64. Bensaid, M., Gary-Bobo, M., Esclangon, A. et al.: The cannabinoid CB, receptor antagonist SR 141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol., 2003, 63, s. 908-914.